Leo Pharma
Leo Pharma, officially known as Leo Pharmaceutical Products Ltd., is a global leader in dermatology and critical care, headquartered in Ballerup, Denmark. Founded in 1908, the company has established a strong presence in Europe, North America, and Asia, focusing on innovative solutions for skin diseases and conditions. With a commitment to research and development, Leo Pharma offers a range of unique products, including topical treatments and biologics for psoriasis, eczema, and other skin disorders. Their dedication to patient-centric care and advanced therapeutic options has positioned them as a trusted name in the pharmaceutical industry. Notable achievements include significant advancements in dermatological therapies, reinforcing their market position as a pioneer in skin health solutions.
DitchCarbon Score
How does Leo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Leo Pharma's score of 54 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Leo Pharma's reported carbon emissions
In 2023, LEO Pharma reported total greenhouse gas (GHG) emissions of approximately 28.9 million tonnes CO2e, comprising 22.9 million tonnes from Scope 1 and 8.5 million tonnes from Scope 2 emissions. The company also recorded significant Scope 3 emissions, amounting to about 288.6 million tonnes CO2e. LEO Pharma has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 GHG emissions by 53% by 2030, using 2019 as the baseline year. Additionally, the company is committed to ensuring that 75% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2026. These initiatives align with LEO Pharma's participation in the Science Based Targets initiative (SBTi), demonstrating its commitment to addressing climate change and contributing to global efforts to limit warming to 1.5°C.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2010 | 2011 | 2012 | 2013 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 12,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,100 | 00,000 | 00,000 | 00,000 | 00,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 388,000 | 000,000 | 000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Leo Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
